Functional evaluation of therapeutic response for a mouse model of medulloblastoma

Transgenic Research

Volumn 19, Issue 5, 2010, Pages 829-840

  Samano, Aislynn K ^a,b   Ohshima Hosoyama, Sachiko ^a   Whitney, Thomas G ^c   Prajapati, Suresh I ^a   Kilcoyne, Aoife ^a   Taniguchi, Eri ^a   Morgan, William W ^b   Nelon, Laura D ^a   Lin, Ai Ling ^a   Togao, Osamu ^d   Jung, Inkyung ^a   Rubin, Brian P ^e   Nowak, Brent M ^c   Duong, Timothy Q ^a   Keller, Charles ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c The University of Texas at San Antonio   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Brain tumor; Cerebellum; Genetically engineered mouse model; Medulloblastoma; MRI

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; CELL SURFACE RECEPTOR; PATCHED RECEPTORS; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ANIMAL; ANIMAL LAMENESS; ARTICLE; ATAXIA; CEREBELLUM TUMOR; DISEASE COURSE; DISEASE MODEL; DRUG SCREENING; ECONOMICS; GENETICS; MEDULLOBLASTOMA; METHODOLOGY; MOUSE; MOUSE MUTANT; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; ATAXIA; BORONIC ACIDS; CEREBELLAR NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG SCREENING ASSAYS, ANTITUMOR; GAIT DISORDERS, NEUROLOGIC; LAMENESS, ANIMAL; MAGNETIC RESONANCE IMAGING; MEDULLOBLASTOMA; MICE; MICE, KNOCKOUT; PROTEASE INHIBITORS; PSYCHOMOTOR PERFORMANCE; PYRAZINES; RECEPTORS, CELL SURFACE;

MUS;

EID: 77956479811     PISSN: 09628819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11248-010-9361-1     Document Type: Article

References (15)

1. Arenkiel BR, Tvrdik P, Gaufo GO, Capecchi MR (2004) Hoxb1 functions in both motoneurons and in tissues of the periphery to establish and maintain the proper neuronal circuitry. Genes Dev 18: 1539-1552.
2. Coughenour LL, McLean JR, Parker RB (1977) A new device for the rapid measurement of impaired motor function in mice. Pharmacol Biochem Behav 6: 351-353.
3. Crawford JR, MacDonald TJ, Packer RJ (2007) Medulloblastoma in childhood: new biological advances. Lancet Neurol 6: 1073-1085.
4. Facklam M, Schoch P, Bonetti EP, Jenck F, Martin JR, Moreau JL et al (1992) Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies. J Pharmacol Exp Ther 261: 1113-1121.
5. Fomchenko EI, Holland EC (2006) Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 12: 5288-5297.
6. Gilbertson RJ (2004) Medulloblastoma: signaling a change in treatment. Lancet Oncol 5: 209-218.
7. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM et al (1995) The molecular basis of Turcot's syndrome. N Engl J Med 332: 839-847.
8. Hamm RJ, Pike BR, O'Dell DM, Lyeth BG, Jenkins LW (1994) The Rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma 11: 187-196.
9. Hann B, Balmain A (2001) Building 'validated' mouse models of human cancer. Curr Opin Cell Biol 13: 778-784.
10. Lafay-Cousin L, Strother D (2009) Current treatment approaches for infants with malignant central nervous system tumors. Oncologist 14(4): 433-444.
11. Polkinghorn WR, Tarbell NJ (2007) Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 4: 295-304.
12. Sakakibara T, Xu Y, Bumpers HL, Chen FA, Bankert RB, Arredondo MA et al (1996) Growth and metastasis of surgical specimens of human breast carcinomas in SCID mice. Cancer J Sci Am 2: 291-300.
13. St Clair WH, Adams JA, Bues M, Fullerton BC, La Shell S, Kooy HM et al (2004) Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 58: 727-734.
14. Taniguchi E, Cho MJ, Arenkiel BR, Hansen MS, Rivera OJ, McCleish AT et al (2009) Bortezomib reverses a post-translational mechanism of tumor genesis for patched1 haploinsufficiency in medulloblastoma. Pediatr Blood Cancer 52(2): 136-144.
15. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F et al (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 11: 1088-1095.